XNAS · Biotechnology
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$8.48+0.24%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
Quality & growth
30%69Positive
- Revenue growth 192.9%
- EPS growth n/a
Valuation
25%54Moderate
- P/E -9.0
- EV/Sales 55.8
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (industry)Top 9%
Gross margin (industry)Top 3%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
69/100Positive
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
6 buy · 0 sell · 2 neutral of 8 votes
TickerWhale reads IBRX's technical setup as strong at 69/100, not yet ranked against the universe in this run. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+23.5%
- vs 50-day+9.5%
Momentum
Constructive
- RSI (14)58 · neutral
- Stochasticbuy
- CCIbuy
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength28· trending
- MACD (12,26,9)buy(histogram 0.025)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 5 buy · 0 sell · 2 neutral.
Result — 6 buy vs 0 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)-9.0 · TTM loss
- P/S (TTM)53.7
- P/B—
- EV/EBITDA—
- EV/Sales55.8
- PEG—
Profitability & returns
- Gross margin99.3%
- Net margin-598.5%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)192.9%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $8.9B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IBRXCurrentImmunityBio | — | 69 | -9.0 | — | — | 55.8 | $8.48 | +0.24% | +192.9% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.